Jiangsu Haijian Frontier Biotechnology Co., Ltd. is a high-end biopharmaceutical innovation company strongly supported by the Jiangsu New Industry * Program. In early 2016, it received Series A funding from a well-known domestic venture capital firm. The company is dedicated to focusing on and providing health solutions for aquaculture animals, specializing in the production and R&D of novel aquatic animal vaccine products, customized R&D, disease clinical diagnosis, and comprehensive technical services for prevention and control. It possesses an industrialization R&D platform and comprehensive outsourcing technical service competitiveness at an internationally advanced level in the creation and development technology of novel genetically engineered vaccines for major aquatic animal diseases, and takes pride in providing environmentally friendly, safe, scientific, and efficient solutions with independent intellectual property rights and supporting products for the healthy and sustainable development of China's aquaculture industry. The company has established a vaccine industry R&D center with first-class domestic facilities in the *** Life Science Park, equipped with a BSL-2 specialized laboratory for pathogenic microorganisms and a veterinary GMP pilot production line, and has built a currently first-class domestic aquatic animal vaccine clinical trial center. The company has established close cooperation with first-class universities and research institutions in the field of aquatic vaccine R&D at home and abroad. All Haijian people are making unremitting efforts to develop the company into a * leader of China's new aquatic vaccine industry.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows